Chief Executive Officer

Chief Medical Officer

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Highs & Lows: Could the microdosing of psychedelics be a key missing piece in the mental health jigsaw?

Psychedelic: Exclusive talk with biopharma company MindMed

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Vice President, Market Access

MindMed is a clinical stage biopharmaceutical company focused on developing innovative treatments for brain health disorders. The Vice President of Market Access will lead the strategic development and execution of initiatives to ensure the successful commercialization of MM120 and future products, with a strong emphasis on patient access and collaboration across various teams.

Sign up with Google

Sign in with Google